---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-024831"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:29.911690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission

## Summary
- SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.
- Secondary endpoints: clinical remission 40%, endoscopic improvement 51%, Modified Mayo Score change -3.7.
- Well tolerated: 6 TEAEs (14%), 1 SAE deemed not drug-related; no drug-related AEs or discontinuations.
- Part A enrollment closed; Part B enrolling monotherapy (SPY001/002/003) and combination cohorts.
- Proof-of-concept data expected mid-2026 for SPY002, Q3 2026 for SPY003; Part B data on track for 2027.

## SEC filing metadata
- accession: 0001628280-26-024831
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/0001628280-26-024831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/syre-20260413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-024831
- JSON: https://secwatch.observer/filing/0001628280-26-024831.json
- Plain text: https://secwatch.observer/filing/0001628280-26-024831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.